Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Phase 2 Recruiting
38 enrolled
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Phase 4 Recruiting
46 enrolled
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Phase 1 Recruiting
30 enrolled
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1 Recruiting
514 enrolled
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Phase 3 Recruiting
158 enrolled
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Phase 1 Recruiting
90 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Phase 2 Recruiting
86 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
MOUNTAINEER-03
Phase 3 Recruiting
400 enrolled
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 Recruiting
710 enrolled
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Phase 1 Recruiting
50 enrolled
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2 Recruiting
130 enrolled
MK-3475-01F
Phase 1/2 Recruiting
190 enrolled
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Phase 2/3 Recruiting
613 enrolled
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Phase 3 Recruiting
500 enrolled
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2 Recruiting
1,130 enrolled
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Phase 1/2 Recruiting
442 enrolled
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Phase 1 Recruiting
27 enrolled
MK-3475-C66
Phase 3 Recruiting
100 enrolled
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 Recruiting
188 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase 1/2 Recruiting
31 enrolled
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Phase 1 Recruiting
542 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Phase 3 Recruiting
408 enrolled
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Phase 2 Recruiting
25 enrolled
TLN-372 in Advanced KRAS Mutant Solid Tumors
Phase 1 Recruiting
240 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
Study of AUBE00 in Patients With Solid Tumors
Phase 1 Recruiting
130 enrolled
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Phase 2 Recruiting
21 enrolled
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 Recruiting
40 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery
Phase NA Recruiting
60 enrolled
KANDLELIT-001
Phase 1 Recruiting
830 enrolled
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Phase 2 Recruiting
33 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1 Recruiting
574 enrolled
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 Recruiting
267 enrolled
A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
Phase 2 Recruiting
300 enrolled
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
542 enrolled
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
81 enrolled
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
Phase 1 Recruiting
42 enrolled
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
260 enrolled
QTX3034 in Patients With KRAS G12D Mutation
Phase 1 Recruiting
250 enrolled
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2 Recruiting
100 enrolled
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
408 enrolled
CEIL
Phase 2 Recruiting
198 enrolled
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Phase 1 Recruiting
24 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled